食管癌靶向治疗研究进展

2012年报告显示食管癌发病率在全球恶性肿瘤中居第5位,死亡率居第4位,与往年数据统计相比,其发病率及死亡率均呈上升趋势。目前对食管癌的治疗已进入多学科综合治疗时代,其中分子靶向治疗也成为研究热点,表现为靶向药物呈现多样化,由单一靶点走向多靶点化,应用于大量Ⅱ~Ⅲ期临床研究中。现今,在食管癌治疗中研究较多的靶向药物主要包括西妥昔单抗、厄罗替尼、曲妥珠单抗、贝伐单抗等。本文通过总结近几年国内外文献资料,对食管癌分子靶向治疗做一综述。

Molecular targeted therapy for esophageal cancer

According to the 2012 estimates,esophageal cancer(EC)was the fifth commonly diagnosed cancer and the forth leading cause of cancer-related death.The incidence and mortality rates of EC have been increasing in China.Combined-modality therapy for EC is well accepted,and molecular targeted therapy becomes a research area.Nowadays,multiple agents have been developed and studied in phase Ⅱ/Ⅲ trials,mainly including cetuximab,erlotinib,trastuzumab,bevacizumab.In this review,we focus on the development of molecular targeted therapy for EC.